Skip to main content

Table 1 Clinical features of patients with MwoA

From: Transcutaneous supraorbital neurostimulation in “de novo” patients with migraine without aura: the first Italian experience

Parameter Timing Mean ± SE p value
Gender   15 F/5 M  
Age (years)   32.9 ± 2.3  
Disease duration (years)   8.3 ± 1.7  
Frequency (days/month) Baseline 4.5 ± 0.24 < 0.001
Follow-up 2.06 ± 0.28
NSAID intake (including acetaminophen) Baseline 3.2 ± 0.6 0.02
Follow-up 1.3 ± 0.4
Triptans intake Baseline 2.4 ± 0.7 0.04
Follow-up 0.9 ± 0.3
Total intake of rescue medication Baseline 5.6 ± 0.4 < 0.001
Follow-up 2.2 ± 0.3
HIT-6 Baseline 62.3 ± 1.4 < 0.001
Follow-up 53.1 ± 1.4
VAS of attack intensity Baseline 8.0 ± 0.1 0.002
Follow-up 6.7 ± 0.2
  1. F female, M male, NSAID non-steroidal anti-inflammatory drugs, HIT-6 Headache Impact Test, VAS Visual Analogue Scale